108 related articles for article (PubMed ID: 21585332)
1. Prospective observation for seven-year's highly active antiretroviral therapy in Chinese HIV-1 infected patients.
He M; Zheng YH; Zhou HY; Mamadou D; Chen Z; Chen X; Yao YH; He Y
Curr HIV Res; 2011 Apr; 9(3):160-5. PubMed ID: 21585332
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a 6-year highly active antiretroviral therapy in Chinese HIV-1-infected patients.
Zhou HY; Zheng YH; He Y; Chen Z; Liu M; Yin W; Liu C
Intervirology; 2010; 53(4):240-6. PubMed ID: 20357493
[TBL] [Abstract][Full Text] [Related]
3. Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort.
Zolfo M; Schapiro JM; Phan V; Koole O; Thai S; Vekemans M; Fransen K; Lynen L
AIDS Res Hum Retroviruses; 2011 Jul; 27(7):727-35. PubMed ID: 20854169
[TBL] [Abstract][Full Text] [Related]
4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
5. [The evaluation of four-year highly active antiretroviral therapy in HIV-1 infected patients].
Deng XJ; He Y; Yang L; Zou SP; Yang H; Zheng YH
Zhonghua Nei Ke Za Zhi; 2011 Mar; 50(3):230-4. PubMed ID: 21600088
[TBL] [Abstract][Full Text] [Related]
6. Virologic outcomes of first-line HAART and associated factors among Chinese patients with HIV in three sentinel antiretroviral treatment sites.
Ruan Y; Xing H; Wang X; Tang H; Wang Z; Liu H; Su B; Wu J; Li H; Liao L; Li J; Wu JW; Shao Y
Trop Med Int Health; 2010 Nov; 15(11):1357-63. PubMed ID: 20868414
[TBL] [Abstract][Full Text] [Related]
7. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
9. Effective treatment of patients in a deep salvage situation with "non-active HAART": experiences with the expert advice system RADATA.
Lorenzen T; Walther I; Stoehr A; Salzberger B; Plettenberg A;
Infection; 2009 Dec; 37(6):528-33. PubMed ID: 19826762
[TBL] [Abstract][Full Text] [Related]
10. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNA cp/ml) during different antiretroviral regimens.
Nicastri E; Palmisano L; Sarmati L; D'Ettorre G; Parisi S; Andreotti M; Buonomini A; Pirillo FM; Narciso P; Bellagamba R; Vullo V; Montano M; Di Perri G; Andreoni M
Curr HIV Res; 2008 May; 6(3):261-6. PubMed ID: 18473790
[TBL] [Abstract][Full Text] [Related]
12. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
Gulick RM; Lalama CM; Ribaudo HJ; Shikuma CM; Schackman BR; Schouten J; Squires KE; Koletar SL; Pilcher CD; Reichman RC; Klingman KL; Kuritzkes DR
AIDS; 2007 Apr; 21(7):813-23. PubMed ID: 17415036
[TBL] [Abstract][Full Text] [Related]
13. Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients.
Llibre JM; Domingo P; del Pozo MA; Miralles C; Galindo MJ; Viciana I; Moreno S; Schapiro JM; Clotet B
J Antimicrob Chemother; 2008 Jan; 61(1):206-9. PubMed ID: 17999972
[TBL] [Abstract][Full Text] [Related]
14. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali.
Germanaud D; Derache A; Traore M; Madec Y; Toure S; Dicko F; Coulibaly H; Traore M; Sylla M; Calvez V; Marcelin AG
J Antimicrob Chemother; 2010 Jan; 65(1):118-24. PubMed ID: 19933171
[TBL] [Abstract][Full Text] [Related]
15. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Xu X; Rodgers A; Lupinacci L; Kumar S; Sklar P; Nguyen BY; Hanna GJ; Hwang C;
Lancet HIV; 2018 May; 5(5):e211-e220. PubMed ID: 29592840
[TBL] [Abstract][Full Text] [Related]
16. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
17. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.
La Rosa AM; Harrison LJ; Taiwo B; Wallis CL; Zheng L; Kim P; Kumarasamy N; Hosseinipour MC; Jarocki B; Mellors JW; Collier AC;
Lancet HIV; 2016 Jun; 3(6):e247-58. PubMed ID: 27240787
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and HIV drug resistance profile of second-line ART among patients having received long-term first-line regimens in rural China.
Wang J; Wang Z; Liu J; Yue Y; Yang S; Huang H; He C; Liao L; Xing H; Ruan Y; Shao Y
Sci Rep; 2015 Oct; 5():14823. PubMed ID: 26445885
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
[TBL] [Abstract][Full Text] [Related]
20. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
Kaufmann GR; Bloch M; Zaunders JJ; Smith D; Cooper DA
AIDS; 2000 May; 14(8):959-69. PubMed ID: 10853977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
